In September 2017, when ADDvise adopted the previous EBITDA target of 10%, the EBITDA margin in the group as per Q3 2017, year to date, was at a level of 6.1%. As per Q3 2020, year to date, the EBITDA margin was at a level of 11.4%.

- We have been working hard to improve the profitability in the group both by optimizing cost and by focusing on the product mix. Based on that and taken additional acquisitions into account I think that we will be able to reach an EBITDA margin of 15% in the long term, says Rikard Akhtarzand, CEO ADDvise Group.
 

For further information, please contact:
Rikard Akhtarzand, CEO
+46 765-25 90 71
rikard.akhtarzand@addvisegroup.se

Important information:

This information is by ADDvise Group AB required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on 12 November 2020 at 08:45 CET.
 

About ADDvise Group
ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se,is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.